Relationship between Monocytes and Stenosis-Related Autologous Arteriovenous Fistula Dysfunction.


Journal

Blood purification
ISSN: 1421-9735
Titre abrégé: Blood Purif
Pays: Switzerland
ID NLM: 8402040

Informations de publication

Date de publication:
2022
Historique:
received: 17 07 2020
accepted: 27 12 2020
pubmed: 11 6 2021
medline: 10 5 2022
entrez: 10 6 2021
Statut: ppublish

Résumé

Arteriovenous fistula (AVF) is considered to be the best choice of vascular access, but the maturation rate and patency rate of AVF are not satisfactory. Many studies have explored the influencing factors of AVF failure but do not involve the direct relationship between monocyte count and AVF failure. This study aims to explore the relationship between monocyte count and AVF dysfunction related to stenosis. From September 2017 to September 2018, basic clinical data and laboratory parameters of patients were collected. All included patients were followed up to September 2019. The stenosis-related AVF failure events that occurred after the patient included in the study and the time of their occurrence were recorded. All patients were divided into 3 groups based on the tertile of monocyte count. Kaplan-Meier method was used to compare the patency rate of AVF in each group. The effects of variables on AVF failure were analyzed. A multivariate Cox regression model with p < 0.05 was included in the univariate Cox regression analysis. A total of 120 patients were included in this study. According to the recorded baseline monocyte count levels, they were divided into 3 groups according to their tertiles, 34 cases in the T1 group (T1 < 0.32 × 109/L), 44 cases in the T2 group (0.32 ≤ T2 < 0.51 × 109/L), and 42 cases in T3 group (T3 ≥0.51 × 109/L). After a median follow-up of 20 months, a total of 31 AVF failure events occurred. Kaplan-Meier survival curves showed that patients with a baseline monocyte count ≥0.51 × 109/L had the lowest patency rate of AVF (log-rank test χ2 = 7.525, p = 0.023). After adjusting to basic clinical data and biochemical indicators, there were statistically significant differences in patency rates of the 3 groups (hazard ratio = 2.774, 95% CI = 1.092-7.043). Monocyte count ≥0.51 × 109/L is an independent risk factor for AVF failure, and AVF failure caused by monocytes may be driven by inflammation.

Sections du résumé

BACKGROUND
Arteriovenous fistula (AVF) is considered to be the best choice of vascular access, but the maturation rate and patency rate of AVF are not satisfactory. Many studies have explored the influencing factors of AVF failure but do not involve the direct relationship between monocyte count and AVF failure. This study aims to explore the relationship between monocyte count and AVF dysfunction related to stenosis.
METHODS
From September 2017 to September 2018, basic clinical data and laboratory parameters of patients were collected. All included patients were followed up to September 2019. The stenosis-related AVF failure events that occurred after the patient included in the study and the time of their occurrence were recorded. All patients were divided into 3 groups based on the tertile of monocyte count. Kaplan-Meier method was used to compare the patency rate of AVF in each group. The effects of variables on AVF failure were analyzed. A multivariate Cox regression model with p < 0.05 was included in the univariate Cox regression analysis.
RESULTS
A total of 120 patients were included in this study. According to the recorded baseline monocyte count levels, they were divided into 3 groups according to their tertiles, 34 cases in the T1 group (T1 < 0.32 × 109/L), 44 cases in the T2 group (0.32 ≤ T2 < 0.51 × 109/L), and 42 cases in T3 group (T3 ≥0.51 × 109/L). After a median follow-up of 20 months, a total of 31 AVF failure events occurred. Kaplan-Meier survival curves showed that patients with a baseline monocyte count ≥0.51 × 109/L had the lowest patency rate of AVF (log-rank test χ2 = 7.525, p = 0.023). After adjusting to basic clinical data and biochemical indicators, there were statistically significant differences in patency rates of the 3 groups (hazard ratio = 2.774, 95% CI = 1.092-7.043).
CONCLUSION
Monocyte count ≥0.51 × 109/L is an independent risk factor for AVF failure, and AVF failure caused by monocytes may be driven by inflammation.

Identifiants

pubmed: 34111871
pii: 000514059
doi: 10.1159/000514059
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

226-232

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Caifang Li (C)

Department of Nephrology, Qingyuan People's Hospital, Qingyuan, China.
Department of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Qiang Li (Q)

Department of Nephrology, Dongguan Hospital of Traditional Chinese Medicine, Dongguan, China.

Jingyun Ou (J)

Department of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Weilong Li (W)

Department of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Department of Nephrology, The Central Hospital of Longhua District, Shenzhen, China.

Baozhang Guan (B)

Department of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Yongping Lu (Y)

Department of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Chen Yun (C)

Department of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Department of Medicine Nephrology, Medical Faculty Mannheim Heideiberg University, Mannheim, Germany.

Berthold Hocher (B)

Department of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Department of Medicine Nephrology, Medical Faculty Mannheim Heideiberg University, Mannheim, Germany.

Bo Hu (B)

Department of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Lianghong Yin (L)

Department of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH